Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company expanded the acquisition and closing of engagements for its full-time physician placement service, strengthened matching, rolled out research and consulting support services, increased the number of contracts for healthcare DX services, and expanded its overseas business platform, primarily in Vietnam.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥3,063 million (YoY +3.3%) |
| Operating profit | ¥205 million (YoY +70.9%) |
| Ordinary income | 201 Millions of yen (profit before tax) (YoY +62.3%) |
| Profit attributable to owners of the parent | ¥114 million (YoY +50.2%) |
| Net income per share | ¥20.88 |
| Equity ratio | End of the current fiscal period 75.6 / End of previous period 71.7 |
| Total assets | ¥6,238 million |
| Net assets | 4,714 Millions of yen (total equity) |
| Cash flows from operating activities | ¥247,417 thousand |
| Cash flows from investing activities | ¥-158,418 thousand |
| Cash flows from financing activities | ¥-246,093 thousand |
| Cash and cash equivalents at end of period | ¥1,514,150 thousand |
| Full-year earnings forecast | Net Sales ¥3,950 million (YoY +3.2%) / Operating profit ¥195 million (YoY +165.1%) / Ordinary income 200 Millions of yen (profit before tax) (YoY +132.0%) / Net income ¥129 million (attributable to owners of the parent) (YoY +131.3%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | 0 yen → 5 yen |
| Depreciation and amortization | 170,462 Thousands of yen (depreciation and amortization) |
| Breakdown of extraordinary income (loss) | No separate line items for special gains and losses were disclosed under IFRS. Discontinued operations included a gain on the sale of shares in a subsidiary of ¥18.901 million and a loss on the sale of shares in a subsidiary of ¥5.902 million. |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 1 company (株式会社医師たちとつくる) |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | None |
| Issued Shares at Period-End | 5,718,600 shares |
| Treasury Shares at Period-End | 245,389 shares |
| Factors Behind Changes in Business Performance | The company expanded the acquisition and closing of engagements for its full-time physician placement service, strengthened matching, rolled out research and consulting support services, increased the number of contracts for healthcare DX services, and expanded its overseas business platform, primarily in Vietnam. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company expanded the acquisition and closing of engagements for its full-time physician placement service, strengthened matching, rolled out research and consulting support services, expanded the adoption of healthcare DX services, and expanded its overseas business platform.